(Total Views: 560)
Posted On: 03/22/2021 7:59:54 AM
Post# of 148899
Re: HHIGambler #83825
"British Rag finds British Docs think British Pharma's vaccine is Just Dandy (Americans Concur)"
Sounds about right.
Everyone is cherry picking things to throw a fit about, the reality is ALL of these vaccines, including Moderna's, were based off reference vaccines from LAST SPRING. NONE will be effective before long, the way things are going.. JNJ's has the best shot according to preliminary studies; it's not widely available yet.
What will likely happen is a dangerous surge of disinhibition ("I'm vaccinated so it's party time" that will just select for variants that evade prior immunity. Let's revisit in six months.. in the meantime, I'm done repeating myself.. keep wearing masks, take precautions even after vaccinating.
https://www.medpagetoday.com/infectiousdisease/covid19/91658
Sounds about right.
Everyone is cherry picking things to throw a fit about, the reality is ALL of these vaccines, including Moderna's, were based off reference vaccines from LAST SPRING. NONE will be effective before long, the way things are going.. JNJ's has the best shot according to preliminary studies; it's not widely available yet.
What will likely happen is a dangerous surge of disinhibition ("I'm vaccinated so it's party time" that will just select for variants that evade prior immunity. Let's revisit in six months.. in the meantime, I'm done repeating myself.. keep wearing masks, take precautions even after vaccinating.
https://www.medpagetoday.com/infectiousdisease/covid19/91658
Quote:
AstraZeneca's COVID-19 vaccine was not protective against mild-to-moderate disease from either the so-called South African variant (B.1.351) or the wild type virus, an interim analysis of phase Ib/II data found.
Overall vaccine efficacy against mild-to-moderate COVID-19 in South Africa was 21.9% (95% CI -49.9 to 59. , and efficacy against B.1.351 was 10.4% (95% CI -76.8 to 54. , reported Shabir Madhi, PhD, of University of the Witwatersrand in Gauteng, South Africa, and colleagues, in the New England Journal of Medicine.
(1)
(0)
Scroll down for more posts ▼